Agenus (Group)

https://www.agenusbio.com

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. *

	Start	2013-11-10 existent
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	Retrocyte Display® technology
	Person	Armen, Garo H. (Agenus 201402 CEO)

	Street	3 Forbes Road
	City	02421-7305 Lexington, MA
	Tel	+1-781-674-4400
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	USD
	Profit	-33,200,000 (2013-12-31)
	Cash	27,400,000 (2013-12-31)

		* Document for »About Section«: Targovax ASA. (3/7/22). "Press Release: Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted with QS-21 STIMULON". Oslo.

		Record changed: 2023-07-10